Anavex Life Sciences Corp.

For the fiscal 2026 first quarter, Anavex reported a net loss of $5.7 million, or $0.06 per share. Cash and cash equivalents were $131.7 million at December 31, with no debt, and operating cash use was $7.1 million after working capital changes. R&D expense was $4.7 million versus $10.4 million in the comparable quarter last year, and G&A was $2.1 million versus $3.1 million. Management attributed lower operating expenses mainly to completion of a large blarcamesine manufacturing campaign in fiscal 2025 and lower clinical trial activity after completion of the ANAVEX 3-71 Phase II schizophrenia study. Forward-looking, management said the EMA reexamination process is expected to last for the first half of this year; the company also said it will submit the existing Phase IIb/III ANAVEX2-73-AD-004 data package to the FDA and continue advancing clinical trial plans in Alzheimer’s, Parkinson’s, Fragile X, and schizophrenia-related disorders.

Christopher Missling framed the quarter around advancing Anavex’s precision-medicine pipeline, especially oral blarcamesine in early Alzheimer’s disease. He emphasized ongoing work with regulators in Europe and the U.S., highlighted the ACCESS-AD consortium as a way to build real-world and regulatory support, and said the company is preparing additional scientific presentations and publications. His tone was confident but measured, repeatedly noting that approval cannot be guaranteed while stressing that the company believes the data package is strong.

Sandra Boenisch emphasized balance sheet strength and lower spending. She said cash was $131.7 million with no debt, operating cash use was $7.1 million, and at the current utilization rate the company has more than 3 years of runway. She cited lower R&D of $4.7 million and G&A of $2.1 million, both down year over year, and linked the decline mainly to the end of a large blarcamesine manufacturing campaign and lower trial activity after the ANAVEX 3-71 schizophrenia study finished.

Analysts focused on the CHMP reexamination process, the FDA pathway, and what data would be added to the EMA resubmission. Management said the EMA process includes a 60-plus 60-day response/review structure and that the package will include AD-004 data, open-label data, ABCLEAR population data, and brain atrophy/clinical correlation data; on the FDA side, management said the Type C meeting was productive and that the full data package will be submitted through the appropriate meeting-request process. Questions also probed the CHMP’s interpretation of sigma-1 wild-type data and the ADCS-ADL endpoint; Missling argued that ADAS-Cog13 and CDR-SB were significant in the wild-type subgroup, that ADCS-ADL was not significant but trended positively, and that the scale may not be sensitive enough in early Alzheimer’s disease.